Daiichi Sankyo

This study tests a new drug combination (datopotamab deruxtecan plus pembrolizumab) against standard treatment for advanced non-small cell lung cancer. It includes about 1,170 adults whose tumors have low PD-L1 levels and no specific gene changes. The goal is to see if the new co…

This phase 3 trial tests whether adding the drug Dato-DXd to standard immunotherapy (pembrolizumab) helps people with advanced or metastatic non-small cell lung cancer live longer without their cancer growing. About 740 adults with a high level of a protein called PD-L1 will be r…

This study tests an experimental drug called patritumab deruxtecan in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to other treatments. About 277 participants will receive the drug to see if it shrinks tumors. The go…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in 200 adults with advanced or spreading solid tumors, including certain ovarian, cervical, endometrial, bladder, and kidney cancers. The goal is to see if the drug can shrink tumors or stop them from growing. Part…

This phase 3 trial compares a newer targeted drug, trastuzumab deruxtecan, against a standard combination of two other drugs (ramucirumab and paclitaxel) in 490 adults with HER2-positive stomach or gastro-esophageal junction cancer that has worsened after initial treatment with t…

This early-stage trial is testing a combination of two drugs—datopotamab deruxtecan (Dato-DXd) and pembrolizumab (Keytruda)—with or without standard chemotherapy in people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumor…

This study tests a newer targeted therapy, trastuzumab deruxtecan (T-DXd), against an older one, trastuzumab emtansine (T-DM1), in about 1,600 people with high-risk HER2-positive breast cancer who still have cancer after initial treatment. The goal is to see if T-DXd can better p…

This study tests an experimental drug called quizartinib, given with chemotherapy, for children and young adults (ages 1 month to 21 years) whose acute myeloid leukemia (AML) has returned or not responded to treatment. The goal is to see if the combination is safe and can help co…

This study compares a new drug, DS-1062a, to the standard chemotherapy docetaxel in about 600 adults with advanced or metastatic non-small cell lung cancer that has worsened after previous treatment. The goal is to see if DS-1062a can slow cancer growth or extend survival better …

This early-stage study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have come back or spread and no longer respond to standard treatments. The main goal is to check the drug's safety and find the…

This early-phase trial tests a drug called HER3-DXd in people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The study includes patients with specific genetic changes (EGFR or KRAS mutations) whose cancer worsened after other treatments.…

This phase 2 study tests a drug called ifinatamab deruxtecan (I-DXd) in 187 people with extensive-stage small cell lung cancer that has already been treated with chemotherapy. The drug is designed to target and kill cancer cells. Researchers are checking how many patients' tumors…

This early-phase study tests a new drug called DS-1001b in 47 people with a specific type of brain tumor (glioma) that has an IDH1 gene mutation and has come back after standard treatments. The main goal is to check the drug's safety and how the body processes it, while also look…

This study tests an experimental drug called valemetostat in people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior treatments. The goal is to see if the drug can shrink tumors and how safe it is. About 155 adults will tak…

This early-stage trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and pembrolizumab (an immunotherapy)—in about 115 adults with advanced breast or non-small cell lung cancer that has a specific marker called HER2. The study has two part…

This phase 3 trial tests whether the experimental drug DS-8201a (trastuzumab deruxtecan) works better than the current standard T-DM1 for people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. About 524 adults who have …

This study tests a new drug, DS-8201a, against standard treatments for people with a specific type of advanced breast cancer called HER2-low. The cancer has spread to other parts of the body and cannot be removed by surgery. About 557 adults whose cancer has already been treated …

This study is tracking over 700 Chinese adults with diabetic peripheral neuropathic pain who are starting mirogabalin. Researchers are monitoring side effects and how well the drug works in everyday medical practice. The goal is to see if mirogabalin is a safe and effective optio…

This observational study tracks how doctors treat advanced triple-negative breast cancer in Canada, the UK, France, and Spain. Researchers will look at real-world data from 760 patients to understand treatment patterns and outcomes. No new drugs are being tested—the goal is to ga…

This study is observing over 2,500 adults with high cholesterol who are taking a combination of bempedoic acid and ezetimibe in routine medical care. Researchers are collecting data on side effects and heart risk to better understand how the treatment works in Asian and Latin Ame…